Ovid Therapeutics Announces Appointment Of Highly-Ranked Biotechnology Research Analyst Dr. Yaron Werber As Chief Financial Officer

NEW YORK--(BUSINESS WIRE)--Ovid Therapeutics Inc. (Ovid), a privately held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain, today announced the appointment of Yaron Werber, M.D., MBA, to the position of Chief Financial Officer, replacing interim CFO Mark Feldberg, who will continue in his role at TradeLink. With nearly 15 years of experience as a highly-ranked biotechnology research analyst at marquee Wall Street firms, Dr. Werber brings a distinguished track record of success to Ovid. He will join effective June 22, 2015, and will report to Dr. Jeremy Levin, Chief Executive Officer and Chairman of Ovid. Dr. Werber will be responsible for all financial planning and reporting, will head investor and public relations, and will support Ovid's business development initiatives.